Literature DB >> 16783578

Immune selective pressure and HLA class I antigen defects in malignant lesions.

Chien-Chung Chang1, Soldano Ferrone.   

Abstract

The revived cancer immune surveillance theory has emphasized the active role the immune system plays in eliminating tumor cells and in facilitating the emergence of their immunoresistant variants. MHC class I molecule abnormalities represent, at least in part, the molecular phenotype of these escape variants, given the crucial role of MHC class I molecules in eliciting tumor antigen-specific T cell responses, the high frequency of HLA class I antigen abnormalities in malignant lesions and their association with a poor clinical course of the disease. Here, we present evidence for this possibility and review the potential mechanisms by which T cell selective pressure participates in the generation of tumor cells with MHC class I molecule defects. Furthermore, we discuss the strategies to counteract tumor cell immune evasion.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16783578     DOI: 10.1007/s00262-006-0183-1

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  43 in total

1.  Mining the plasma immunopeptidome for cancer peptides as biomarkers and beyond.

Authors:  Heather D Hickman; Jonathan W Yewdell
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-25       Impact factor: 11.205

2.  High numbers of PDCD1 (PD-1)-positive T cells and B2M mutations in microsatellite-unstable colorectal cancer.

Authors:  Jonas Janikovits; Meike Müller; Julia Krzykalla; Sandrina Körner; Fabian Echterdiek; Bernd Lahrmann; Niels Grabe; Martin Schneider; Axel Benner; Magnus von Knebel Doeberitz; Matthias Kloor
Journal:  Oncoimmunology       Date:  2017-11-06       Impact factor: 8.110

3.  Role of Tumor-Associated Macrophages in the Clinical Course of Pancreatic Neuroendocrine Tumors (PanNETs).

Authors:  Lei Cai; Theodoros Michelakos; Vikram Deshpande; Kshitij S Arora; Teppei Yamada; David T Ting; Marty S Taylor; Carlos Fernandez-Del Castillo; Andrew L Warshaw; Keith D Lillemoe; Soldano Ferrone; Cristina R Ferrone
Journal:  Clin Cancer Res       Date:  2019-01-22       Impact factor: 12.531

4.  Multiple structural and epigenetic defects in the human leukocyte antigen class I antigen presentation pathway in a recurrent metastatic melanoma following immunotherapy.

Authors:  Chien-Chung Chang; Giuseppe Pirozzi; Shao-Hsuan Wen; I-Hsin Chung; Bau-Lin Chiu; Simona Errico; Monica Luongo; Maria Luisa Lombardi; Soldano Ferrone
Journal:  J Biol Chem       Date:  2015-09-17       Impact factor: 5.157

Review 5.  The biology of interleukin-2 efficacy in the treatment of patients with renal cell carcinoma.

Authors:  Antonio Romo de Vivar Chavez; Michael E de Vera; Xiaoyan Liang; Michael T Lotze
Journal:  Med Oncol       Date:  2009-01-16       Impact factor: 3.064

6.  A novel role of HLA class I in the pathology of medulloblastoma.

Authors:  Courtney Smith; Mariarita Santi; Bhargavi Rajan; Elisabeth J Rushing; Mi Rim Choi; Brian R Rood; Robert Cornelison; Tobey J MacDonald; Stanislav Vukmanovic
Journal:  J Transl Med       Date:  2009-07-12       Impact factor: 5.531

7.  Quantification of HLA class I molecules on renal cell carcinoma using Edman degradation.

Authors:  Juliane S Stickel; Natalie Stickel; Jörg Hennenlotter; Karin Klingel; Arnulf Stenzl; Hans-Georg Rammensee; Stefan Stevanović
Journal:  BMC Urol       Date:  2011-01-20       Impact factor: 2.264

8.  The innate immune system recognizes and regulates major histocompatibility complex class I (MHCI) expression on MHCIlow tumor cells.

Authors:  Bent Rubin; Joëlle Riond; Laetitia Courtiade; Nicolas Roullet; Jean-Edouard Gairin
Journal:  Cancer Immun       Date:  2008-09-11

9.  Mutation or loss of Wilms' tumor gene 1 (WT1) are not major reasons for immune escape in patients with AML receiving WT1 peptide vaccination.

Authors:  Antonia Busse; Anne Letsch; Carmen Scheibenbogen; Anika Nonnenmacher; Sebastian Ochsenreither; Eckhard Thiel; Ulrich Keilholz
Journal:  J Transl Med       Date:  2010-01-21       Impact factor: 5.531

Review 10.  Testing the theory of immune selection in cancers that break the rules of transplantation.

Authors:  Ariberto Fassati; N Avrion Mitchison
Journal:  Cancer Immunol Immunother       Date:  2009-12-22       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.